Utomilumab is under clinical development by Pfizer and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Utomilumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Utomilumab overview

Utomilumab (PF-05082566) is under development for the treatment of mantle cell lymphoma, ovarian cancer, colorectal cancer, follicular lymphoma, breast cancer, metastatic breast cancer and triple negative breast cancer. The drug candidate is a new molecular entity and is administered by intravenous route. It acts by targeting 4-1BB.

It was also under development for the treatment of relapsed or refractory diffuse large B-cell lymphoma, squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, squamous cell carcinoma of the uterine cervix, pancreatic cancer, gastric cancer, urothelial bladder cancer, metastatic hepatocellular carcinoma, sarcoma, renal cell carcinoma, relapsed or refractory acute myeloid leukemia (AML), thymoma (Thymic Epithelial Tumor), follicular lymphoma and anaplastic thyroid cancer, hematological tumor and solid tumor.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Utomilumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.